8-K - S. Jaggi Compensation Update


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
  
Form 8-K
 
 
CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
Date of Report (Date of earliest event reported):  April 5, 2014
 
 
Intermolecular, Inc.
(Exact Name of Registrant as Specified in Charter) 
 



Delaware
 
001-35348
 
20-1616267
(State or Other Jurisdiction
of Incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)
 



3011 N. First Street
San Jose, California
 
95134
(Address of Principal Executive Offices)
 
(Zip Code)
 
(408) 582-5700
(Registrant's Telephone Number, Including Area Code)

 
N/A
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))









ITEM 5.02.    DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS

Intellectual Property Licensing Commission Incentive Program for General Counsel and Senior Vice President of Intellectual Property

On April 5, 2014, the Compensation Committee of the Board of Directors of Intermolecular, Inc. (the “Company”) approved a new intellectual property licensing commission incentive program for Sandeep Jaggi, J.D., Ph.D., the General Counsel and Senior Vice President of Intellectual Property of the Company. Under the terms of the new program, Dr. Jaggi is eligible to receive one or more future cash payments equal to 0.5% of revenue as and when received by the Company from a specified potential customer engagement, subject to his continued employment.


SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
 
INTERMOLECULAR, INC.
 
 
 
Date: April 9, 2014
By:
/s/ DAVID E. LAZOVSKY
 
 
David E. Lazovsky
 
 
President and Chief Executive Officer